Alcon

The Great Place to Work Certification Programme is a three-year framework designed to build and sustain a high-performance culture in organisations. T(...)

Early data in Swiss share trading on Monday indicated banks and fund managers in the EU were directing their deals towards three destinations - the Zu(...)

Fresh tariff rhetoric from US president Donald Trump affected global stocks on Tuesday with Europe’s benchmark Stoxx 600 index down 0.3 per cent. Add(...)

Novartis plans to spin off its Alcon eyecare business to shareholders and buy back up to $5 billion in stock as chief executive Vas Narasimhan refocus(...)

Novartis chief executive Joe Jimenez will step down on February 1st and hand over to drug development chief Vas Narasimhan to decide the fate of $50 b(...)

The Irish division of eyecare business Alcon, which last year marked 25 years in Cork, saw profits and turnover decline in 2016 after incurring big co(...)

Sales at the Irish division of Novartis eyecare business Alcon jumped more than 5 per cent to €41.78 million last year. However, profit before tax fe(...)

Swiss drugmaker Novartis has appointed a new head of its Alcon eye care division after the company fell short of fourth-quarter earnings expectations(...)

Pharmaceutical firm Novartis saw its second quarter earnings fall by 7 per cent as the strength of the US dollar hit sales. The company said it(...)

Novartis, the world’s biggest drugmaker by sales, reported first-quarter profits that beat analysts’ estimates as the company begins to benefit from a(...)